|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07H 19/06 | (2006.01) |
| C07H 19/10 | (2006.01) | ||
| A61K 31/7068 | (2006.01) | ||
| A61P 31/14 | (2006.01) |
| (11) | Number of the document | 2604620 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13152340.9 |
| Date of filing the European patent application | 2004-04-21 | |
| (97) | Date of publication of the European application | 2013-06-19 |
| (45) | Date of publication and mention of the grant of the patent | 2016-06-29 |
| (46) | Date of publication of the claims translation | 2016-09-12 |
| (30) | Number | Date | Country code |
| 474368 P | 2003-05-30 | US |
| (72) |
Clark, Jeremy, US
|
| (73) |
Gilead Pharmasset LLC,
c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Modifikuoti fluorintų nukleozidų analogai |
| Modified fluorinated nucleoside analogues |
| Payment date | Validity (years) | Amount | |
| 2023-04-08 | 347.00 EUR |